5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | December 27, 2013 12:30 pm

Five pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader[1] database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Ocera Therapeutics, Inc. (OCRX[2]) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. In Portfolio Grader’s specific subcategory of Earnings Revisions, OCRX also gets an A. For more information, get Portfolio Grader’s complete analysis of OCRX stock[3].

Johnson & Johnson (JNJ[4]) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

Bristol-Myers Squibb Company (BMY[6]) is seeing ratings go up from a C last week to a B this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

Watson Pharmaceuticals’ (WPI[8]) ratings are looking better this week, moving up to an A from last week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

This week, Repros Therapeutics’ (RPRX[10]) ratings are up from a B last week to an A. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. OCRX: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=OCRX
  3. For more information, get Portfolio Grader’s complete analysis of OCRX stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=OCRX
  4. JNJ: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  5. For more information, get Portfolio Grader’s complete analysis of JNJ stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  6. BMY: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  7. For more information, get Portfolio Grader’s complete analysis of BMY stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  8. WPI: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  9. For more information, get Portfolio Grader’s complete analysis of WPI stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  10. RPRX: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  11. For more information, get Portfolio Grader’s complete analysis of RPRX stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  12. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  13. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2013/12/5-pharmaceutical-stocks-to-buy-now-ocrx-jnj-bmy-2/

Copyright ©2024 InvestorPlace unless otherwise noted.